Novel patent-free formula for

    the treatment of pathologically high sympathetic tone

    and autonomous dysfunction

    in many rare disease




    Open Source since 2022
  • An Orphan Composite Formula

    For patients suffering from severe pathological hypersympathetic tone.




    Hypersympathetic tone is a complex condition characterized by overactivity of the sympathetic nervous system, leading to a range of physiological disturbances. Appropriate management requires a multifaceted approach to alleviate symptoms and improve the quality of life of those affected. Hypersympathicotonia is of particular importance in people suffering from extreme conditions such as Oshtoran's syndrome, for which amitradicaine was first used. However, this diagnosis is not a mandatory requirement for its use. Your doctor will know when to use Amitradicain.


    About Amitradicain


    Amitradicain is a composite medicinal formulation (clinically synergistic composite) carefully designed to modulate sympathetic nerve activity in a clinically synergistic manner to relieve and control symptoms associated with hypersympathetic tone. Amitradicain has been administered in specialized clinical settings since its use began in 2022. It is a compound of several already long-served drugs that act synergistically. Normally doctors prescribe it for SC or IM administration as a prescription formula to be manufactured individually by local pharmacies.


    Why a brand name for a composite pharmaceutical?


    In the vast landscape of pharmaceuticals, the naming of a composite drug serves multiple purposes beyond mere identification. A recognizable and consistent name can prevent errors in prescribing, dispensing, and administering medications. Amitradicain, being a composite of multiple active ingredients, benefits from a branded name, ensuring therapeutic adherence, fostering patient trust, and potentially enhancing clinical outcomes.


    Promising feedback


    To further rank and disseminate the effects of the amitradicaine composite formulation and its branding on treatment adherence, safety, and efficacy, data have been collected continuously since 2022 to date (as of September 2023) from now 196 clinicians worldwide with several hundred patients, and the trend is strongly increasing. These clinicians treat or have treated patients with extremely rare conditions and symptoms of severe hypersympathetic dysfunction for whom all available on-label medications did not work and for whom the use of composite formulas is permitted at their place of professional practice. The database is dynamic, and new information is added regularly to reflect the ongoing worldwide use of Amitradicain and its effects (see reference papers below in the References section).


    The importance of the name Amitradicain


    The data available to us to date showed a significant improvement in adherence and objective clinical parameters in patients administered amitradicaine under its name compared to an anonymized version of the same composite agent. Based on the current record, the increased treatment adherence assumes that a noceboeffect due to polypharmacy is avoided. The synergy between a clear name with recognition and thorough patient education seems to create a conducive therapeutic environment. Clear communication between providers and patients is critical to ensure that the brand name does not mislead or provide a false sense of security, but rather helps ensure that treatment is adhered to and understood. Naming such drugs may improve patient acceptance, adherence, and potentially clinical outcomes in the treatment of conditions such as hypersympathetic dysfunction. Further research and adoption of such naming may optimize patient education and clinical outcomes for complex medical conditions. This is also the reason why the manufacturing formulation remains off-patent, however, the name "Amitradicain" is protected and copyrighted as a protection against any form of abuse.

  • Dysfunctional nervous system

    The Amitradicaine formula was developed as a powerful stabilizer

  • This is Amitradicain

    A composite medication for patients with rare diseases

    A composite medication

    Amitradicain is meticulously formulated to counteract the perilous cascade effects arising during autonomic dysfunction. Such malfunctions can set off a series of escalating physiological challenges, potentially leading to severe outcomes. By targeting key points within this cascade, Amitradicain seeks to halt the onset and progression of these complications, emphasizing a proactive stance in maintaining autonomic balance.


    What Amitradicaine is not

    Amitradicain is not a commercially available medication produced by a pharmaceutical company. It is a composite formula. A specialized and experiemced pharmacist must prepare it following a physician’s order, in accordance with the legal framework of the treatment location. This is not a commercial platform for selling the drug. Its primary aim is to disseminate knowledge about this non-patented composite medication to physicians worldwide.

    Observed effects with Amitradicaine

    Amitradicaine has been used but 192 physicians on 682 patients worldwide since 2022 after informed consent and within the scope of the local laws, rules and regulations, safety first. The below stated results could be observed. This list is subject to updates as new data will reach the designer of the formula and his lab.

    • Marked sympathicolysis, averaging a 62.9% reduction as per AVCB 2.9 evaluations.
    • Equilibration of sympathetic and parasympathetic pathways.
    • Decrease in catecholaminergic activity by up to 70%, as indicated by body fluid examinations.
    • Up to an 80% decline in significant catecholamine surges.
    • Noticeable reduction in blood sugar levels, with diabetes symptoms subsiding by the fourth day.
    • Reduction in autonomic dysfunction episodes by up to 55%.
    • Blood pressure reduced by 20%.
    • Significant anxiolysis, especially targeting anxiety stemming from degenerative changes in the substantia nigra and basal ganglia.

    Contraindications & adverse effects

    Amitradicain is a synergistic combination of highly potent medications, each with its own potential adverse effects and risks. All contraindications and warnings related to Amitradicain’s individual components are applicable. For those with cardiac issues, especially heart failure or blocks, 24/7 monitoring and access to essential life-saving equipment are vital for the initial 90 days of treatment (or longer). This extends even more to those with other cardiovascular or respiratory conditions. Patients on Amitradicain should avoid operating vehicles. Please refer to the interaction guidelines for each ingredient in this formulation. Further warnings and our disclaimer should be read carefully by your physician.

  • broken image

    The Amitradicain formula is




    100mg injection solution


    5mg injection solution


    4mg injection solution






    30mg injection solution






    2mg injection solution***





    Possible booster effects directly caused by C18H250 are

    currently under real life testing. First results show drastic effects beyond all expectations. However, glucose level might drop significantly due to the blood glucose reducing effects of tramadol. This potentially highly dngerous effects seems to be boosted as well. Therefore Amitradicain with an DXM booster should be considered strictly contraindicated for patients with diabetes of all types, especially those on medication or insulin repleacement therapy.


    * For simplicity, the above stated formula is basic summation that does not reflect any chemical synergies between compounds.

    ** When C17H13ClN4 is taken orally separately (solution for injection not available in many countries), the molecular formula changes, but the clinical effect remains within an acceptable range, with effects comparable to those observed with a complete injectable solution.

    *** Some relevant scientific papers partially depict the use of C17H13ClN4 in flowcharts as when it is taken orally 20 minutes before the main injection instead of being part of the injection solution. Both variants are to be considered equivalent in terms of clinical results with not significantly different reported outcomes.


    Warning & Disclaimer

  • broken image

    What it means for you that Amitradicain is a composite medication.


    Please note: adhere strictly to the directives provided by your physician and the laws of the state/country you reside in.

  •  How Amitradicain was formulated

    ...and why is it patent-free?

    The last resort

    In a specialized network practice dedicated to patients with severe rare diseases, Dr. Ali Asgari, a rather young physician and pharmacologist, was approached by a team facing a perplexing case. The patient was diagnosed with a rare disease marked by intense hypersympathicotonia as well as autonomic dysfunction. Traditional avenues had been exhausted without significant progress.


    Recognizing the gravity of the situation, Dr. Asgari embarked on an exhaustive research endeavor. He revisited his old university scripts and textbooks, meticulously analyzing studies and case reports that might offer a hint of a solution. Night after night, he immersed himself in literature, connecting dots from various sources and drawing on his deep knowledge of pharmacology.


    It was during one of these intensive study sessions that he recalled a lecture from his academic days. His professor had discussed the potential of synergetic composite medications, emphasizing the benefits that could be harnessed when certain drugs were combined. Inspired by this recollection, Dr. Asgari began formulating a unique composite medication tailored to the patient’s specific needs.


    The result was a compound that showed promising effects, offering a new therapeutic avenue for the challenging case at hand. Dr. Asgari’s dedication and rigorous research approach were instrumental in this breakthrough, demonstrating the profound impact of continuous learning and innovation in the medical field.


    The result was a compound that showed promising effects, offering a new therapeutic avenue for the challenging case at hand. Recognizing the potential benefits for a wider patient demographic, Dr. Asgari, in a spirit of altruism and dedication to the medical community, decided not to patent the formula. Instead, he openly shared Amitradicain with other clinics, focusing especially on those dealing with rare or even nameless diseases.


    As a consequence, Dr. Asgari and LCG Research began receiving a plethora of feedback from various clinics worldwide. This invaluable bedside data, sourced directly from diverse clinical settings, is continuously and meticulously analyzed, ensuring that Amitradicain evolves in line with the real-world needs of patients and clinicians, further exemplifying the commitment of Dr. Asgari to advancing medical knowledge and patient care.

  • For whom and when?

    The Amitracain formula was designed to reduce a pathologically hypersympathetic tone

    Rare diseases and very rare diseases

    Disorders without a name

    Failure of regular (orphan) drugs

  • Your Amitradicain prescription



    You suffer from a rare disease with a pathologically too high tone of the so called "sympathetic nervous system".


    No alternatives work

    All regular drugs failed in your case.


    Detailed information and consent

    Your doctor will provide you with comprehensive information about the risks and benefits of using Amitradicain.


    Prescription of the formulation

    Your doctor will provide you with comprehensive information about the risks and benefits of using Amitradicain and will prescribe amitradicaineonly if you give fully informed consent. The legal burden is borne exclusively by the physician prescribing the formula.



    With this prescription, you go to a pharmacy that has the legal authorization to produce pharmaceutical products. This means "your" Amitradicaine is made especially for you.


    What does Amitradicain cost?

    Based on the prices for its ingredients Amitradicaine is a very affordable medical drug.


    Return to your doctor

    Once your amitradicaine is ready for use (after 2 days to 6 weeks, depending on the country and situation) go back to your doctor, who will explain how to use it and discuss with you how to proceed in detail.


    What about LCG Research & legal status

    The creators of the synergetic composite drug Amitradicain do not get to know about any prescription, because they have completely renounced patent protection. No profit is to be made with your condition. However, the name of the composite formula "Amitradicain" is protected by copyright, so that no pharmaceutical company can usurp this, from our point of view, groundbreaking composite medicine. In addition, prescribing physicians are encouraged to report unexpected effects, both positive and adverse, to the laboratory so that this information can be quickly made known to the medical community (even without a legal obligation to do so).

  • Amitradicaine

    Created in the European Union

  • Warnings &


    Amitradicaine is an exceptionally potent compounded medication designed for specific use. Its use must be under the risk-conscious direction and supervision of careful medical professionals (meaning experienced medical doctors) who are familiar with the patient's history, medical history, and treatment requirements. Amitradicaine was designed to treat a specific patient. Its efficacy, safety, risks, and hazards may therefore vary unpredictably with use in a broader patient population. Therefore, it should be prescribed only where the law permits composite drug preparations and where the prescribing physician himself/herself is the only person responsible for the health and life of the patient. All patients administered Amitradicaine are strongly discouraged from driving vehicles of all kind. In addition, Amitradicaine contains active ingredients that may cause serious interactions in some individuals, some of which have to be considered potentially life-threatening. The developer of the Amitradicain formula and the medical facility for which he works strongly discourage the use of Amitradicain outside of clinical trials or other individual situations permitted by the legal framework of the jurisdiction where the prescribing physician works. Any liability arising from this website, related links, information, media or publications is hereby disclaimed by Dr. Asgari and LCG Research in any manner whatsoever. Each physician prescribing amitradicaine bears full, complete and sole responsibility for anything that happens to the patient or a third party in connection with this composite medication.


  • How Amitradicain is made after

    the mandatory patient training

    The use of the amitradicaine composite is subject to the legislation of the country in which you are located.

    broken image
  • References

    Honda, R., Asgari, A., Simon, N., & Diamandis, C. (2023). Amitradicain - Managing Oshtoran Syndrome (Case Study II). In Zenodo ePub: Bde. 11/23 (2.1). Zenodo ePub. https://doi.org/10.5281/zenodo.10086913


    Atanackovic D, Dalgaard-Mikkelsen S: Procaine and autonomic innervation. Proc Soc Exp Biol Med. 1950 May;74(1):55-6. doi: 10.3181/00379727-74-17807. PMID: 15430388


    Honda, R., Asgari, A., & Nathan, S. (2023). Amitradil - A safer alternative to Amitradicain for managing of Oshtoran Syndrome in patients with heart issues and all types of diabetes. In Zenodo ePub: Bde. 10/23. Zenodo. https://doi.org/10.5281/zenodo.10003956


    Cooper, I: Procaine injection of the globus pallidus in Parkinsonism. Psychiatr Q. 1954 Jan;28(1):22-3. doi: 10.1007/BF01567035. PMID: 1315568


    Johansen J, Yang J, Kleinhaus AL. Actions of procaine on specific nociceptive cells in leech central nervous system. J Neurosci. 1984 May;4(5):1253-61. doi: 10.1523/JNEUROSCI.04-05-01253.1984. PMID: 6726331; PMCID: PMC6564940


    Redding VJ, Rees JR. Early changes in collateral flow following coronary artery ligation: the role of the sympathetic nervous system. Cardiovasc Res. 1968 Jul;2(3):219-25. doi: 10.1093/cvr/2.3.219. PMID: 4970325.


    Tudor, A., Asgari, A., Nathan, S., & Honda, R. (2023). The impact of branding on patient reception and therapeutic efficacy of composite pharmaceutical Amitradicain in Oshtoran Syndrome management. In Zenodo: Bde. 10/23. Zenodo. https://doi.org/10.5281/zenodo.1003053


    Diamandis, C., Asgari, A., & Kaufmann, M. (2023). Follow-up data for the novel pharmaceutical formula Amitradicain. In Zenodo: Bde. 11/23 (Nummer ePub). Zenodo. https://doi.org/10.5281/zenodo.10057500

  • The Amitradicain™ experience

    This video explains how to deal with a prescription for amitradicaine (more specifically its ingredients). In case of questions or issues please contact your prescribing physician directly.


    What makes Amitradicain unique

    It is not a new innovation but a novel approach


    What you should know about Amitradicain

    In the realm of rare diseases, ‘Orphan Drugs’ have been the conventional route. However, they often come with laborious development timelines, high costs, and restrictive patents. Amitradicain offers an alternative: a composite formula that leverages the synergetic potential of existing drugs.


    Speed of Development


    Developed in just over 14 months with the final formula having been available since Summer 2022, Amitradicain defies the traditional timelines associated with pharmaceutical development. Its fast-track status is due to its composition of already approved, fully licensed and well-studied medications as a formula, not a product.


    Freedom in therapeutic choices


    Originating from a European ethos that permits physicians to prescribe custom formulas at their own risk, Amitradicain takes full advantage of what the Germans call “Therapiefreiheit.” This permits the immediate use of Amitradicain post-informed consent, democratizing access to effective treatment options across global healthcare systems.


    Clinical synergy: More than the sum of its parts


    Hundreds of physicians worldwide have reported a notable synergetic effect when administering Amitradicain as a composite, compared to using its individual components separately. This phenomenon has driven the unprecedented speed of its acceptance among clinicians treating patients with a pathologically, out of control hypersympathic tone (a clinical situation that can be life-threatening) for whom other medications have failed.


    Legality and Liability


    Being a composite of existing medications, Amitradicain comes with no attached patents, allowing any qualified pharmacist to produce it (please study the Warnings & Disclaimer section carefully). While we, LCG Research, provide the formula as a philanthropic gift, all liability resides with the prescribing physician. The brand name Amitradicain is only protected to prevent commercial usurpation or misuse.


    A gift to global healthcare


    By providing Amitradicain as an open-source formula, LCG Research aims to empower physicians and help patients who have run out of options. We are committed to maintaining the integrity of this groundbreaking composite, thereby offering a fresh, effective, and rapid solution to rare diseases that have been hitherto neglected.

  • Legal status of Amitradicain

    For the EU. Seek advice locally in other countries.

    Legal foundation

    Amitradicin is a formulation that must be adapted to a specific patient by a licensed doctor. It is not an industrially prefabricated medicinal product. If a doctor in the EU prescribes a composite medicinal product prepared in a pharmacy, special regulations apply that differ from those for industrially manufactured medicinal products.

    Individualized Preparation

    Compounded medicines in pharmacies are typically prepared for a specific patient based on a doctor’s prescription. This means the medicine is not manufactured in advance and stored. This applies to Amitradicain.

    Regulation and Supervision

    The preparation of compounded medicines is subject to national laws and must comply with Good Manufacturing Practices (GMP). The pharmacy is responsible for quality assurance. This applies to Amitradicain.

    Approval and Registration

    Unlike industrially produced medicines, compounded medicines do not require formal approval from medicinal authorities. However, the pharmacist must ensure that production meets legal requirements.

    Responsibility of Doctor and Pharmacist

    The prescribing doctor is responsible for deciding to prescribe a custom compounded medicine. The pharmacist is accountable for its correct preparation and dispensation. This applies to Amitradicain.

    Documentation and Traceability

    The pharmacy must keep accurate records of the production process, ingredients used, and dispensation of the medicine. This applies to Amitradicain.

    Patient Education

    The pharmacist should inform the patient about the use, dosage, and potential side effects of the compounded medicine. In mane EU states it is allowed to prescribe the ingredient seprately with the patient mixing their composite injection themselves. This applies to Amitradicain.w

  • Contact LCG Research

    General questions for experts only. No sales, no treatment, no online medicine.